Free Trial
NASDAQ:FHTX

Foghorn Therapeutics Q1 2025 Earnings Results & Report

Foghorn Therapeutics logo
$2.07 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$2.06 0.00 (-0.24%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Foghorn Therapeutics met analyst earnings expectations and beat on revenue in its Q1 2025 results, released May 14, 2025. The company reported EPS of -$0.30 versus the -$0.30 consensus estimate, while revenue of $5.95 million topped the $4.96 million estimate by $990.00 thousand.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Foghorn Therapeutics EPS Results

Actual EPS
-$0.30
Consensus EPS
-$0.30
Beat/Miss
Met Expectations
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Foghorn Therapeutics Revenue Results

Actual Revenue
$5.95 million
Expected Revenue
$4.96 million
Beat/Miss
Beat by +$990.00 thousand
YoY Revenue Growth
N/A

Foghorn Therapeutics Q1 2025 Earnings FAQ

Foghorn Therapeutics (NASDAQ:FHTX) reported earnings of -$0.30 per share for Q1 2025, matching the consensus estimate of -$0.30. The report was announced on Wednesday, May 14, 2025.

Foghorn Therapeutics reported revenue of $5.95 million for Q1 2025, against a consensus estimate of $4.96 million.

Foghorn Therapeutics Earnings Headlines

HC Wainwright Analysts Increase Earnings Estimates for FHTX
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
See More Foghorn Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Foghorn Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Foghorn Therapeutics and other key companies, straight to your email.

About Foghorn Therapeutics

Foghorn Therapeutics (NASDAQ:FHTX) is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for cancer. Its research centers on chromatin regulatory systems, which help control how genes are expressed and can contribute to disease when disrupted.

The company’s Gene Traffic Control platform is designed to identify drug targets within these systems. Foghorn has developed investigational programs targeting chromatin regulators, including components of the BAF complex; its candidates remain in development and are not approved medicines.

Founded in 2015 and based in Cambridge, Massachusetts, Foghorn has pursued research collaborations with other pharmaceutical companies, including Eli Lilly. Adrian Gottschalk has served as the company’s chief executive officer.

View Foghorn Therapeutics Profile